



Presented by the Duke Cancer Network  
In Collaboration with the Duke Cancer Institute

# Navigating Immunotoxicities from Cancer Therapies

March 17, 2023



Duke Cancer Institute



Duke Cancer Institute

Presented by the Duke Cancer Network  
In Collaboration with the Duke Cancer Institute

## Navigating Immunotoxicities from Cancer Therapies

March 17, 2023

### Location

JB Duke Hotel  
230 Science Dr. Durham, NC

### Registration

Register online at <https://bit.ly/NavImmuno23>

**Contact/Questions** If you are interested in exhibiting at this conference, please contact Beth Tanner at 919-971-3627 or [beth.tanner@duke.edu](mailto:beth.tanner@duke.edu)

### Description:

Immunotherapeutic approaches to cancer treatment use a patient's own immune system to target cancer cells. The side effects associated with traditional treatment options such as chemotherapy and radiation make immunotherapeutic options appealing. The immune system can identify cancer cells in one of two ways: by recognizing tumor-specific antigens or mutations, or by recognizing tumor associated antigens. Immunotherapy offers effective treatment options for cancer that offer long-lasting effects with improved overall survival and treatment tolerance. Immunotherapy can also cause organ specific toxicities or immune related adverse events. The recognition of these toxicities and their management is forefront for the clinicians caring for the oncology patient. The Duke Cancer Institute Center for Immunotherapy and the Duke Cancer Network are partnering to utilize a multidisciplinary team of oncology and immunology experts and researchers to educate on immunotoxicities occurring in cancer patients as well as management for these toxicities.

### Objectives:

- Identify common immune related adverse events seen from the use of cancer immunotherapeutic agents
- Recognize various immunotoxicities effect on specific organ systems
- Examine organ-specific clinical cases, diagnostic tests and current guidelines used to guide management and treatment of the patient experiencing an immune-related adverse event

## Joint Accreditation Statement



In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

## Credit Statement

**Physicians:** Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Nursing:** Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 7 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

**Pharmacists:** Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 7 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-23-128-Lo4-P/T.



JOINT ACCREDITATION<sup>™</sup>  
INTERPROFESSIONAL CONTINUING EDUCATION

**Disclaimer:** The information provided at this activity is for continuing medical education purposes only and is not meant to substitute the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

## Course Directors

**Afreen Shariff, MD, MBBS**  
Assistant Professor of Medicine  
Director, Duke Endo-Oncology Program  
Associate Director  
Multi-Disciplinary Toxicity Program  
DCI Center for Cancer Immunotherapy

**Linda Sutton, MD**  
Associate Chief Medical Officer  
Duke Network Services  
Professor of Medicine  
Duke University Health System

## Duke Faculty

**Coral Giovacchini, MD**  
Assistant Professor of Medicine

**Meenal Kheterpal, MD**  
Assistant Professor of Dermatology

**Michel Khouri, MD**  
Associate Professor of Medicine

**David Ortiz-Melo, MD**  
Assistant Professor of Medicine

**Suma Shah, MD**  
Assistant Professor of Neurology

**Sophia Weinmann, MD**  
Assistant Professor of Medicine

## Honored Guest Faculty

**Michael Dougan, MD, PhD**  
Assistant Professor of Medicine  
Massachusetts General Hospital  
Harvard Medical School

**Jon McDunn, PhD**  
Executive Director  
Project Data Sphere

**Kerry Reynolds, MD**  
Clinical Director, Inpatient Oncology Units  
Director, Severe Immunotherapy  
Complications Service  
Massachusetts General Hospital

**Yousuf Zafar, MD**  
Senior Vice President, Medical Informatics  
Change Healthcare  
Adjunct Professor of Medicine  
Duke University School of Medicine

7:15 a.m. – 7:55 a.m.

7:55 a.m. – 8:00 a.m.

8:00 a.m. – 8:50 a.m.

8:50 a.m. – 9:30 a.m.

9:30 a.m. – 10:00 a.m.

10:00 a.m. – 10:30 a.m.

10:30 a.m. – 11:10 a.m.

11:10 a.m. – 11:40 a.m.

11:40 a.m. – 12:10 p.m.

12:10 p.m. – 12:55 p.m.

1:00 p.m. – 1:30 p.m.

1:30 p.m. – 2:00 p.m.

2:00 p.m. – 2:30 p.m.

2:40 p.m. – 3:20 p.m.

3:20 p.m. – 4:30 p.m.

4:30 p.m. – 4:35 p.m.

## Registration/ Breakfast

### Welcome

Afreen Shariff, MD, MBBS

### Keynote Address: Immune Mediated Toxicities: The Past, Present and the Future

Kerry Reynolds, MD

### Endocrine Adverse Events

Afreen Shariff, MD, MBBS

### Renal Adverse Events

David Ortiz-Melo, MD

### Break and Exhibitor Showcase

### Gastrointestinal Adverse Events

Michael Dougan, MD, PhD

### Rheumatologic Adverse Events

Sophia Weinmann, MD

### Dermatologic Adverse Events

Meenal Kheterpal, MD

### Lunch

### Cardiac Adverse Events

Michel Khouri, MD

### Neuromuscular Adverse Events

Suma Shah, MD

### Break and Exhibitor Showcase

### Pulmonary Adverse Events

Coral Giovacchini, MD

### Panel Discussion: Rethinking Toxicity Management

Afreen Shariff, MD, MBBS

Featuring: Michel Khouri, MD; Jon McDunn, PhD; David Ortiz-Melo, MD; Kerry Reynolds, MD; Yousuf Zafar, MD

### Closing Remarks